Rafael Fonseca, MD, breaks down the integration of CAR T-cell therapy as a treatment for early relapsed multiple myeloma.
|Articles|September 7, 2022
Supplements and Featured Publications
- Diagnosis and Trial Options in Sarcoma
- Volume 1
- Issue 1
Exploring the Interaction of MDM2 and p53 in Soft Tissue Sarcomas
Advertisement
Articles in this issue
almost 4 years ago
Dr. Martin-Broto on Future Research Directions of Soft Tissue Sarcomaalmost 4 years ago
Dr. Blay on Treatment Considerations in Soft Tissue Sarcomasalmost 4 years ago
Dr. LoRusso on the Benefit of Genetic Sequencing in Sarcomasabout 4 years ago
Dr. Martin-Broto on MDM2 and P53 in Soft Tissue Sarcomaover 4 years ago
Dr. LoRusso on the Efficacy of BI 907828 in Solid TumorsAdvertisement
Related to this article
Dana M. Chase, MD, joins Angeles Alvarez Secord, MD, MHSc, to discuss mocertatug rezetecan in gynecologic malignancies.
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Jill Gilbert, MD, discusses the journey of lifelong learning in hematology/oncology.
Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
Maurie Markman, MD, discusses conflicts of interest in cancer care.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC
3
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
4
Five Under 5: Top Oncology Videos for the Week of 8/16
5